Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a mix of positive and negative factors. Positive developments include strong financial metrics, successful funding, and promising results in the Fabry disease program. However, significant risks such as funding challenges, regulatory approval uncertainties, and competitive pressures weigh heavily. The Q&A section highlighted management's evasive responses, particularly regarding Fabry partnerships, which could dampen investor confidence. Without a market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral sentiment for the stock price in the short term.
Key Financial Performance
Funding Raised Over $130 million raised since the start of 2025 through nondilutive license fees, milestone payments, and equity financing.
Fabry Disease Program - eGFR Slope Positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks across all patients in the STAAR study, showing improved kidney function and stabilization in cardiac function. This marks a notable departure from the historical renal decline characteristic of Fabry disease.
Fabry Disease Program - Cardiac Function Stabilization in cardiac function, including stability of cardiac structure and cardiac biomarkers, which is significant as cardiovascular disease is the most common cause of death in Fabry disease patients.
Fabry Disease Program - Enzyme Replacement Therapy Demonstrated ability to withdraw from enzyme replacement therapy, showcasing potential as a one-time durable treatment option for Fabry disease.
Neurology Pipeline - ST-503 Received Fast Track designation for ST-503, an investigational epigenetic regulator for patients with intractable pain due to small fiber neuropathy (SFN). This designation underscores the high unmet patient need and urgency to develop non-opioid treatment alternatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ST-920 (Isaralgagene Civaparvovec): Rolling submission of a Biologics License Agreement (BLA) to the FDA for Fabry disease treatment under an accelerated approval pathway. Nonclinical and clinical modules submitted, with the antibody assay companion diagnostic accepted by the FDA. Manufacturing and testing of process validation lots completed with acceptable results, and the first commercial lot manufactured. Positive clinical data presented, showing improved kidney and cardiac function, and potential as a one-time durable treatment option.
ST-503: Received Fast Track designation from the FDA for treating small fiber neuropathy (SFN). Phase I/II STAND study activated at six clinical sites. Preclinical safety and pharmacology data published in Science Translational Medicine.
ST-506: Advancing clinical trial application (CTA)-enabling activities for prion disease treatment. Completed GLP toxicology study with ongoing analysis.
Fabry Disease Program Commercialization: Actively seeking a commercial partner for the Fabry disease program. Engaged in discussions with multiple potential partners to secure commercialization.
Neurotropic Capsid Collaborations: Announced a third neurology capsid license agreement with Eli Lilly to deliver genomic medicines for up to five central nervous system disease targets.
Funding: Raised over $130 million in 2025 through nondilutive license fees, milestone payments, and equity financing.
Transition to Clinical Stage Neurology Company: Shifted focus to neurology with six clinical sites activated for the Phase I/II STAND study in chronic neuropathic pain.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Market Uncertainty: The company operates in a backdrop of regulatory and market uncertainty, which could impact the approval and commercialization of its therapies.
Cash Runway and Funding Challenges: Sangamo faces limited cash resources and is dependent on securing adequate additional funding to continue operations and complete key milestones, including the BLA submission for ST-920.
Fabry Commercialization Partner: Securing a commercial partner for Fabry disease remains a critical challenge, with ongoing but prolonged discussions with potential partners.
Regulatory Approval Risks: The approval of ST-920 under the accelerated approval pathway is subject to FDA review and acceptance, which carries inherent risks.
Supply Chain and Manufacturing Risks: The completion of the chemistry, manufacturing, and controls (CMC) module and manufacturing of commercial lots are critical milestones that could face delays or issues.
Competitive Pressures: The company operates in a competitive landscape for gene therapies, which could impact its market position and ability to secure partnerships.
Economic and Strategic Execution Risks: The company is assessing all strategic options for its assets, indicating potential challenges in aligning its strategy with financial and operational goals.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cash runway and funding: Sangamo's ability to continue operations and achieve its goals is contingent on securing adequate additional funding. The company is actively seeking ways to raise capital, including strategic partnerships and commercialization agreements.
Fabry disease program (ST-920): The rolling submission of a Biologics License Application (BLA) to the FDA for ST-920 is in progress, with the nonclinical and clinical modules already submitted. The chemistry, manufacturing, and controls (CMC) module is expected to be completed by summer 2026, subject to securing additional funding. The program aims to transform the Fabry treatment landscape with a one-time durable treatment option.
Neurology pipeline (ST-503 and ST-506): The ST-503 program for small fiber neuropathy (SFN) has received Fast Track designation from the FDA, with six clinical sites activated for the Phase I/II STAND study. Preclinical studies for ST-506, targeting prion disease, are advancing with completed toxicology studies and ongoing analysis.
Collaborations and partnerships: Sangamo continues to position itself as a collaborator of choice, with a third neurology capsid license agreement signed with Eli Lilly. The company is also in active discussions to secure a commercial partner for the Fabry program and other strategic collaborations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more color on the revised timing for the Fabry BLA submission? What PPQ and other CMC-related activities are the primary gating factors here? Can you comment on the status of the Fabry partnership discussions and whether recent leadership changes at CBER have had any impact on those discussions?
A:The revised timing for the Fabry BLA submission is due to the need to complete CMC activities, which are on the critical path for filing. The FDA has provided detailed guidance to maximize the submission's success. Additionally, the company is managing cash carefully to ensure a runway for a Fabry partnership. Regarding partnerships, discussions are ongoing with new partners after previous ones exited due to regulatory uncertainty. Leadership changes at CBER have not been specifically mentioned as impacting discussions.
Q:Have you had any additional interactions with the FDA recently or have any additional FDA interactions planned, specifically relating to the acceptance of the eGFR slope as a primary endpoint? Has anything changed given the recent FDA changes?
A:The company last spoke to the FDA in October of the previous year, where the agency reiterated that the eGFR at 1 year could be used for accelerated approval. They are halfway through the rolling submission and do not plan further interactions unless the FDA's approach to gene therapy changes.
Q:On prime disease, does the timeline for the first in-human trial for STAC-BBB capsid also account for partnered programs? Is there an aspect of the approach that makes it more suitable for some indications versus others, or is the decision to use the intrathecal AAV9 for neuropathic pain just a matter of timing?
A:The decision to use AAV9 for neuropathic pain was based on its effectiveness and safety when given intrathecally, and the program started before the STAC-BBB capsid was known. The STAC-BBB capsid is being advanced by neurological companies with strong resources, and the company is collaborating with them to move their programs forward.
Q:Review of Unclear Management Responses
A:Management appeared to avoid directly addressing whether recent leadership changes at CBER had any impact on Fabry partnership discussions. Additionally, the response to the question about the timeline for partnered programs using the STAC-BBB capsid lacked specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAV integration
BLA FDA
BLA module
BLA summer
CDRH premarket
CEO afternoon
Dubois Stringfellow
FDA basis
Head
Nathalie Dubois
Officer update
SFN
ST approval
STAAR study
Stringfellow Chief
addition
afternoon today
capsid
designation
eGFR slope
function
license agreement
manufacturing
pathway submission
patient need
patient study
pharmacology
platform presentation
review
site Phase
study ST
submission BLA
treatment option
validation lot
SGMO Transcript
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call highlights financial and strategic challenges, including NASDAQ delisting and funding needs, which overshadow progress in clinical trials. The Q&A reveals uncertainties in business development and data disclosure timelines. Despite some positive regulatory signals, the overall sentiment is negative due to financial instability and execution risks.
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call reflects a mix of positive and negative factors. Positive developments include strong financial metrics, successful funding, and promising results in the Fabry disease program. However, significant risks such as funding challenges, regulatory approval uncertainties, and competitive pressures weigh heavily. The Q&A section highlighted management's evasive responses, particularly regarding Fabry partnerships, which could dampen investor confidence. Without a market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral sentiment for the stock price in the short term.
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlighted strong financial metrics, including a sufficient cash runway into 2026 and positive clinical data across multiple programs. While the Q&A revealed some uncertainties in partnership negotiations, the FDA's supportive stance on the Fabry disease program and ongoing interest in other platforms provide optimism. The call's overall tone was positive, with strong clinical results and financial health suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong financial performance with an $18 million upfront fee from Eli Lilly and potential for $1.4 billion in future earnings. The Fabry program shows significant clinical progress, with patients showing improved quality of life and stable cardiac function. The Q&A section reveals positive sentiment from analysts and high potential adoption rates for ST-920. Despite an equity offering, the cash runway is extended, and cost reductions are significant. Overall, the optimistic guidance and strong clinical data suggest a positive stock price movement.
SGMO Slides
SGMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
